2014年7月13日,梯瓦药物DuoResp Spiromax获欧盟委员会(EC)批准,用于适合糖皮质激素和长效β2-肾上腺素受体激动剂组合疗法的慢性阻塞性肺病(COPD)和哮喘(asthma)患者的治疗。
DuoResp Spiromax(budesonide & formoterol fumarate dihydrate,布地奈德 福莫特罗富马酸盐二水合物)是一种新的多剂量干粉吸入剂,由布地奈德(budesonide)和福莫特罗(formoterol)组成。布地奈德是一种吸入性皮质类固醇(ICS),用于治疗哮喘患者和COPD患者潜在的炎症;福莫特罗是一种速效和长效β2激动剂(LABA),用于缓解哮喘患者和COPD患者的支气管收缩(bronchoconstriction )。Spiromax吸入器采用独特的呼吸驱动技术,能够递送一致剂量的药物。
DuoResp Spiromax的开发,旨在改善药物的易用性,并递送一致剂量的药物。由于吸入器技术的落后,许多哮喘和COPD患者存在治疗不足(under-treated)的情况,这导致了额外的就诊次数以及需要紧急护理等形式的不必要负担。
DuoResp Spiromax将进入吸入性皮质类固醇/长效β2激动剂(ICS/LABA)固定剂量组合吸入剂细分市场,在全球范围内,ICS/LABA药物销售额达139亿美元,欧洲市场销售额达44亿美元。
DuoResp Spiromax (formoterol/budesonide) has been launched for use in adults with asthma or chronic obstructive pulmonary disease (COPD), where use of an inhaled corticosteroid and a long-acting beta2 agonist is appropriate.
The breath-actuated dry powder inhaler is available in two strengths:
•160/4.5 (formoterol fumarate dihydrate 6 microgram, budesonide 200 microgram per dose) - equivalent to Symbicort 200/6 Turbohaler
•320/9 (formoterol fumarate dihydrate 12 microgram, budesonide 400 microgram per dose) - equivalent to Symbicort 400/12 Turbohaler.
In asthma, the 160/4.5 inhaler may be used both as regular maintenance treatment and as needed in response to symptoms. The 320/9 inhaler must be used with a separate reliever.
In COPD, both inhalers are indicated for symptomatic treatment in patients with a forced expiratory volume in one second (FEV1) <50% predicted normal and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
The Spiromax device has a design similar to that of pressurised metered-dose inhalers. There are three steps to using the inhaler: open, breathe and close. No priming is required. Dose confirmation is provided by a 'click' sound, lactose taste and a dose indicator.
Name | DuoResp Spiromax |
---|---|
Agency product number | EMEA/H/C/002348 |
Active substance |
budesonide / formoterol fumarate dihydrate |
International non-proprietary name (INN) or common name |
budesonide / formoterol |
Therapeutic area | AsthmaPulmonary Disease, Chronic Obstructive |
Anatomical therapeutic chemical (ATC) code | R03AK07 |
Publication details
Marketing-authorisation holder |
Teva Pharma B.V. |
---|---|
Revision | 0 |
Date of issue of marketing authorisation valid throughout the European Union | 28/04/2014 |
Contact address:
Teva Pharma B.V.
Computerweg 10
3542DR Utrecht
The Netherlands
Name | Language | First published | Last updated |
---|---|---|---|
DuoResp Spiromax : EPAR - Public assessment report | (English only) | 20/05/2014 | |
CHMP summary of positive opinion for DuoResp Spiromax | (English only) | 21/02/2014 |